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Objectives: This study aimed to determine the frequency of benzodiazepine (BDZ) use in a 
large sample of patients with obsessive-compulsive disorder (OCD) and ascertain the type of 
BDZ used and the correlates and predictors of BDZ use in OCD. 
Methods: The sample consisted of 955 patients with OCD from a comprehensive, cross-
sectional, multicentre study conducted by the Brazilian Research Consortium on Obsessive-
Compulsive Spectrum Disorders between 2003 and 2009. 
Results: The rate of BDZ use over time in this OCD sample was 38.4%. Of individuals 
taking BDZs, 96.7% used them in combination with other medications, usually serotonin 
reuptake inhibitors. The most commonly used BDZ was clonazepam. Current age, current 
level of anxiety and number of additional medications for OCD taken over time significantly 
predicted BDZ use.  
Conclusions: This is the first study to comprehensively examine BDZ use in OCD subjects, 
demonstrating that it is relatively common, despite recommendations from treatment 
guidelines. Use of BDZs in combination with several other medications over time and in 
patients with marked anxiety suggests that OCD patients taking BDZs may be more complex 
and more difficult to manage. This calls for further research and clarification of the role of 
BDZs in the treatment of OCD.  
 





Despite the fact that obsessive-compulsive disorder (OCD) has been considered an anxiety 
disorder until the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5; American Psychiatric Association, 2013), the usefulness of benzodiazepines 
(BDZs) in OCD has not been studied much. Most evidence regarding this issue comes from 
case reports and open-label studies with small numbers of participants. Thus, one open-label 
trial in 14 patients (Stein et al., 1992) showed that alprazolam was not efficacious in the 
treatment of OCD. With regards to clonazepam, one randomised, double-blind, placebo-
controlled trial conducted in 27 OCD patients (Hollander et al., 2003) failed to demonstrate 
efficacy in OCD, but another study involving 28 patients and using a randomised, double-
blind, multiple crossover design (Hewlett et al., 1992) reported that clonazepam was as 
efficacious in OCD as clomipramine. Several case reports also suggested the effectiveness of 
clonazepam in OCD (Bodkin and White, 1989; Bacher, 1990; Hewlett et al., 1990; Ross and 
Pigott, 1993). Following reports that BDZs might be useful to augment OCD treatment with 
serotonin reuptake inhibitors (SRIs) (e.g., Pigott et al., 1992; Leonard et al., 1994), one 
randomised controlled trial conducted in 37 patients (Crockett et al., 2004) showed that a 
combination of sertraline and clonazepam did not lead to a better outcome in OCD than a 
combination of sertraline and placebo. 
 
In view of these results, recent treatment guidelines either do not mention BDZs as a potential 
treatment for OCD (Baldwin et al., 2014) or state that BDZs “have not demonstrated efficacy and are 
not recommended in the treatment of OCD” (Katzman et al., 2014, p. 31). The latter applies to both 
BDZ monotherapy and their adjunctive use. However, most investigators commented that BDZs 
might still be useful in at least some cases of OCD. Thus, it has been suggested that BDZs might be 
useful for OCD patients with co-occurring anxiety disorders (Hollander et al., 2003) or in those who 
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have not responded to SRIs, either as monotherapy (Hewlett et al., 1992) or as augmentation 
treatment (Hewlett et al., 1992; Hollander et al., 2003; Crockett et al., 2004).  
 
Considering that the role of BDZs in the treatment of OCD has not been sufficiently 
investigated and the general popularity of BDZs in the treatment of anxiety disorders 
(Starcevic, 2014), it does not come as a surprise that, despite recommendations from 
treatment guidelines, BDZs seem to be relatively commonly prescribed for OCD. For 
example, a survey of the prescribing practices in nine international OCD centres has found 
that BDZs were used as augmenting (adjunctive) agents by 24.9% of patients (Van 
Ameringen et al., 2014). Clonazepam was the most commonly prescribed BDZ in this 
survey, followed by bromazepam, alprazolam and lorazepam. A study of the characteristics 
of office-based visits by OCD patients in the United States between 2003 and 2010 reported 
that BDZs were prescribed in 29.0% of such visits (Patel et al., 2014). An earlier survey from 
the United States revealed that 35.5% of OCD patients were treated with BDZs and that BDZ 
treatment was frequently associated with co-occurring mood and anxiety disorders (Blanco et 
al., 2006). This study also reported that concurrent SRIs were administered in two-thirds of 
the cases in which BDZs were prescribed.   
 
These data suggest that, despite not being officially considered a treatment for OCD, BDZs 
are still commonly administered to OCD patients. However, such practice has been 
understudied. There appears to be a tendency to prescribe BDZs in OCD to augment therapy 
with SRIs, but the reasons for this remain unclear. Therefore, the present study was 
undertaken with several goals. First, we aimed to determine the frequency of BDZ use in a 
large sample of OCD patients, both as monotherapy and in conjunction with other 
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medications. Second, we wanted to ascertain the type of BDZs used. Finally, the study aimed 
to investigate the correlates and predictors of BDZ use in OCD. 
 
Consistent with the findings stated above, we hypothesised that between 25% and 35% of 
OCD patients were taking BDZs and that most of them were taking BDZs as augmentation 
therapy. We expected clonazepam to be used more often than other BDZs because of the 
aforementioned studies reporting some efficacy of this medication for OCD and the 
associated suggestion about certain serotonergic effects of clonazepam (Hewlett et al., 1992). 
We also hypothesised that BDZ use was more likely in older and female patients with OCD, 
based on studies in various countries showing that BDZ use tends to be positively correlated 
with age and female gender (Lagnaoui et al., 2004; Neutel, 2005; Petitjean et al., 2007; 
Hollingworth and Siskind, 2010; Firmino et al., 2011; Holm et al., 2012; Sonnenberg et al., 
2012; Brunoni et al., 2013; Cloos et al., 2015; Olfson et al., 2015).  
 
In addition, we predicted that BDZ use in OCD reflected a more severe, more chronic and 
more complex illness, considering that BDZs are not the first-line treatment for OCD and that 
they would therefore be more likely to be prescribed to patients who failed to respond to 
standard monotherapy with SRIs or were otherwise treatment-resistant. In view of the well-
documented anxiolytic effects of BDZs, we expected BDZs to be administered more often to 
individuals with higher levels of anxiety and more prominent co-occurring anxiety disorders 
and anxiety-inducing obsessions. The latter include aggressive, sexual, moral and religious 
obsessions (unacceptable/taboo thoughts), because they are usually experienced as 
particularly distressing, disturbing and anxiety-provoking (e.g., Brakoulias et al., 2013). This 
last hypothesis is supported by one case series, which reported that aggressive obsessions 
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responded favourably to clonazepam treatment, either alone or in combination with 




The sample for this study was drawn from a cross-sectional research conducted by the 
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders in seven 
specialised, university-affiliated sites in Brazil between 2003 and 2009. The design and 
characteristics of this project were described by Miguel et al. (2008). The present study 
included 955 patients who were at least 18 years of age.  
 
The key inclusion criterion was the primary diagnosis of OCD. Only the presence of 
schizophrenia, dementia, mental retardation or any other condition that precluded 
understanding of the assessment procedure constituted grounds for exclusion. Participants 
were recruited from various mental health facilities and other referral sources and via 
advertisements, self-help groups and patient and professional organisations. The study was 
approved by the institutional review boards in all sites and all participants signed consent 
forms after the study had been explained to them.  
 
Assessment instruments 
The assessment procedures were described in detail by Miguel et al. (2008). The instruments 
that provided data for the purposes of the present study are listed below.   
 
The Socio-Demographic and Clinical Questionnaire. This instrument was developed for the 
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders project. It 
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provided demographic information and data on the course and treatment of OCD. Some of its 
components are based on patient self-report, whereas others elicit information through a face-
to-face clinical interview. Data on participants’ use of BDZs and other medications, as well 
as data pertaining to the onset and duration of OCD, were obtained from this questionnaire.   
 
The Structured Clinical Interview for the DSM-IV Axis I Disorders (SCID-I; First et al., 
1997). The SCID-I was used to establish that OCD was the primary diagnosis and to ascertain 
the presence of co-occurring mental disorders. The researchers were trained in the use of the 
SCID-I, as well as other clinician-administered measures listed below; inter-rater reliability 
figures for all these instruments were excellent (Miguel et al., 2008).  
 
The Yale-Brown Obsessive-Compulsive Scale (Y-BOCS; Goodman et al., 1989). The Y-
BOCS is a semi-structured, clinician-administered interview, widely used to measure the 
severity of OCD. It consists of a checklist of obsessions and compulsions and a 10-item 
severity scale. Up to 3 most prominent obsessions and compulsions are rated for severity, 
providing separate scores for the severity of obsessions and compulsions and a total Y-BOCS 
score, denoting the overall severity of OCD.  
 
The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS; Rosario-Campos et 
al., 2006). The DY-BOCS has both a self-report component and clinician-rated component. It 
was used to assess the severity of six symptom dimensions of OCD: (1) obsessions about 
harm due to aggression/injury/violence/natural disasters and related compulsions (“aggressive 
obsessions”); (2) sexual/moral/religious obsessions and related compulsions; (3) obsessions 
about symmetry/”just-right” perceptions and compulsions to count or order/arrange; (4) 
contamination obsessions and cleaning compulsions; (5) hoarding obsessions and 
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compulsions, and (6) miscellaneous obsessions and compulsions (e.g., relating to somatic 
concerns or superstitions).  
 
The Beck Anxiety Inventory (BAI; Beck et al., 1988) and The Beck Depression Inventory 
(BDI-II; Beck et al., 1996) are widely used, psychometrically sound, self-report instruments 
that assess the severity of anxiety and depressive symptoms, respectively. Both instruments 
consist of 21 items, with each item being rated on a four-point scale and total scores on the 
BAI and BDI-II being obtained by summing the item scores. 
 
Data analyses 
Descriptive statistics and preliminary analyses were conducted in SPSS 22.0. Before 
conducting the analyses, missing values for the key variables were imputed using the 
expectation-maximization algorithm in SPSS. Thus, 41 of 21965 data points (0.19%) were 
imputed and Little’s MCAR test indicated that data were missing completely at random: χ2 = 
33.31, df = 22, p = 0.058. 
 
Chi-square tests were used to compare categorical variables between the groups of BDZ users 
and non-users. Non-parametric Mann-Whitney U tests were used to compare the 
demographic and relevant clinical variables as the distributions for these variables were 
positively skewed (except for the Y-BOCS total score) and Kolmogorov-Smirnov tests 
indicated that the variables were not normally distributed.  
 
Logistic regression analyses were conducted in MPlus where any BDZ use over time (present 
or absent) was regressed on current age, gender, Y-BOCS total score, duration of OCD, 
number of additional medications for OCD being taken over time, BDI-II score, BAI score, 
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DY-BOCS aggressive obsessions score and DY-BOCS sexual/moral/religious obsessions 
score. Site of recruitment was entered in the analysis as a level 2 between-subjects variable in 
order to account for between-site differences in the patterns of BDZ use. Given the possibility 
of collinearity between some of the variables in the analysis, Variance Inflation Factor (VIF) 
statistics were reviewed in SPSS. No VIF values were greater than 3.4 for the overall sample 
or 7.3 when examining collinearity within any given site.  
 
Results 
Of the 955 participants, 367 (38.4%) took BDZs at some point since the onset of their OCD, 
with 213 (58%) of BDZ users being female. Rates of BDZ use varied from 28.0% to 73.3% 
according to site of recruitment. Of those individuals taking BDZs, 12 (3.3%) used them as 
monotherapy, 342 (93.2%) took them with at least one SRI over time and 143 (39.0%) used 
BDZs with at least one antipsychotic medication since the onset of OCD. The most 
commonly used BDZ was clonazepam (278 patients or 75.7% of all BDZ users), followed by 
diazepam (122; 33.2%) and alprazolam (107; 29.2%). There were 250 (68.1%) participants 
who took only one type of BDZ, whereas 94 (25.6%) used two types of BDZs over time and 
23 (6.3%) took three types of BDZs throughout the duration of their OCD.  
 
Table 1 shows that BDZ users and BDZ non-users did not differ significantly with respect to 
the demographic characteristics, except for BDZ users’ older mean current age. Table 2 
compares BDZ users and BDZ non-users in terms of the relevant clinical variables. The 
duration of OCD was significantly longer among BDZ users and they also had significantly 
more prominent sexual/moral/religious obsessions and higher mean scores on both the BDI-II 
and BAI. The mean number of additional medications for OCD was significantly greater 
among BDZ users. 
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[Tables 1 and 2 about here] 
Table 3 shows that, except for panic disorder with agoraphobia, BDZ users and BDZ non-
users did not differ significantly with regards to the lifetime rates of co-occurring anxiety 
disorders. Results of the logistic regression analyses are summarised in Table 4, with current 
age, BAI score and number of additional medications for OCD emerging as significant 
predictors of BDZ use. 
[Tables 3 and 4 about here] 
 
Discussion 
To the best of our knowledge, this is the first study focusing on the investigation of clinical 
predictors of BDZ use in OCD subjects. Well over one-third (38.4%) of individuals with 
OCD in this large Brazilian sample were treated with BDZs at some stage of their illness. 
This is higher than the previously reported rates of BDZ use in OCD, which ranged from 
24.9% to 35.5% (Blanco et al., 2006; Patel et al., 2014; Van Ameringen et al., 2014). A 
possible reason for the higher rate reported in this study is that we combined current and past 
BDZ use, whereas other studies did not assess past BDZ use. Another reason may be that 
study participants were drawn from tertiary care settings, possibly reflecting a more severely 
ill sample. The variation between the Brazilian sites in terms of the frequency with which 
BDZs were used is likely a consequence of different treatment orientations (predominantly 
pharmacotherapeutic vs. predominantly psychotherapeutic), different settings (inpatient vs. 
outpatient) and differences in patient characteristics (public vs. private). Also, rates of BDZ 
use were reported to be higher in Brazil than in most developed countries (Kapczinski et al., 




The vast majority (96.7%) of patients using BDZs took them in conjunction with other 
pharmacological agents, most commonly SRIs. This is in accordance with suggestions that 
use of BDZs to augment SRIs in OCD might be useful (Hewlett et al., 1992; Hollander et al., 
2003; Crockett et al., 2004). 
 
In accordance with our hypothesis, clonazepam was the most frequently used BDZ. It is 
possible that this finding reflects the fact that the study was conducted in academic centres 
specialised in OCD, where prescribers were more likely to be aware that some research 
suggested possible efficacy of clonazepam for OCD. However, clonazepam, along with 
diazepam, is also the most commonly used BDZ in Brazil (Noto et al., 2002; Firmino et al., 
2011; Brunoni et al., 2013).  
 
Users of BDZs were significantly older than the participants who never took BDZs, and 
current age was a significant, but weak predictor of BDZ use in this sample of OCD 
individuals. This is in agreement with findings about the use of BDZs in various countries 
(Lagnaoui et al., 2004; Neutel, 2005; Petitjean et al., 2007; Hollingworth and Siskind, 2010; 
Holm et al., 2012; Sonnenberg et al., 2012; Cloos et al., 2015; Olfson et al., 2015), as well as 
Brazil (Firmino et al., 2011; Brunoni et al., 2013), and may reflect tendencies in the general 
use of BDZs. Contrary to our hypothesis and findings from other studies, the proportions of 
women among BDZ users and BDZ non-users were almost identical, and female gender did 
not emerge as a significant predictor of BDZ use in OCD individuals. It is uncertain whether 
these findings are related to OCD or some other factor.      
 
Our hypothesis that BDZ use in OCD is related to a greater severity, chronicity and 
complexity of OCD was only partially supported. The severity of OCD did not differ between 
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BDZ users and BDZ non-users and did not predict use of BDZs. In contrast, the mean 
duration of OCD was significantly longer among BDZ users, suggesting a more chronic 
course of OCD in those who were taking BDZs. Due to the cross-sectional nature of the 
study, the direction of possible causality between the chronic course of OCD and use of 
BDZs could not be ascertained. Furthermore, the duration of OCD did not emerge as a 
significant predictor of BDZ use.  
 
The use of additional medications for OCD over time was more common in BDZ users, as 
indicated by the significantly greater mean number of additional medications for OCD in this 
group than in the group of BDZ non-users; the number of additional medications for OCD 
also predicted the use of BDZs. These findings suggest that BDZs are more likely to be used 
when OCD is more complex or more difficult to manage, prompting clinicians to try various 
pharmacological agents. Similar polypharmacy in OCD has been reported by others (Blanco 
et al., 2006; Van Ameringen et al., 2014). The present study sheds more light on this issue by 
suggesting that BDZs may often be used as part of various augmentation strategies.  
 
The finding that lifetime rates of most co-occurring anxiety disorders did not differ 
significantly between BDZ users and BDZ non-users was surprising, because it has been 
suggested that BDZs might be useful in OCD patients with co-occurring anxiety disorders 
(Hollander et al., 2003) and that higher rates of co-occurring anxiety disorders were expected 
among BDZ users. However, BAI-derived findings do suggest that BDZ users were 
characterised by currently higher general anxiety levels and that these were a significant, but 
weak predictor of BDZ use. These somewhat discrepant findings may indicate that clinicians 
take more into account patients’ general anxiety levels than the presence of co-occurring 




We found that of all OCD dimensions, only sexual/moral/religious obsessions were more 
prominent in BDZ users than in BDZ non-users. However, neither the DY-BOCS 
sexual/moral/religious obsessions score nor the DY-BOCS aggressive obsessions score 
predicted BDZ use. These findings suggest that use of BDZs in this sample of OCD 
individuals was unrelated to the severity of these obsessions, but it remains to be ascertained 
whether patients with certain OCD features might be more responsive to BDZs, used either 
alone or in combination with SRIs.  
 
The use of BDZs has been controversial, largely due to their habit-forming properties and 
some of their adverse effects, such as sedation and psychomotor impairment. Clinicians 
treating OCD patients need to balance the potentially detrimental effects of BDZs with the 
benefit of a quick relief of anxiety with these agents.   
 
This study has a number of limitations. First, it is based on cross-sectional research, which 
did not allow us to examine any effects of BDZs or to assess changes in OCD and its 
treatment over time. Likewise, it was not possible to obtain data on the longitudinal patterns 
of BDZ use, including its duration and any changes in the doses of BDZs. Second, the study 
relied on participants’ recall about medications that they have taken since the onset of their 
OCD, which is subject to recall bias. Third, data on the factors that might have influenced the 
prescription of BDZs (e.g., clinician or patient preferences and previous patient experience 
with BDZs) were not collected. Further, information on the use of hypnotic medications was 
not recorded. Since this class of pharmacological agents includes a number of BDZs, the rate 
of BDZ use in this sample may have been somewhat underestimated. However, our primary 
focus in this study was BDZ use for OCD and anxiety, not for sleep disturbance. Finally, the 
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interpretation of the findings should take into account tertiary care settings and the country in 
which the study was conducted; these factors also limit the generalizability of the findings.    
 
In conclusion, this study sheds more light on the neglected issue of BDZ use in OCD and 
confirms that use of BDZs in adult OCD patients is more common than what would be 
expected on the basis of the available OCD treatment guidelines. Clonazepam was the most 
commonly used BDZ in this large Brazilian sample of OCD patients. It appears that BDZs 
are typically used in combination with several other pharmacological agents over time and in 
patients with marked anxiety, suggesting an association between BDZ use on one hand and 
greater complexity of OCD and difficulty in managing OCD on the other. This study did not 
find a link between BDZ use and specific features of OCD, raising a question as to whether 
there are any aspects of OCD itself that might suggest a need for treatment with BDZs. A 
paucity of high-quality studies of the efficacy of BDZs for OCD calls for further research. 
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(n = 367) 
BDZ non-users  
(n = 588) 
  p 
 Mean (Median; SD) Mean (Median; SD) Mann-Whitney 
U statistic  
 
Current age (in years) 37.58 (35; 12.80) 34.73 (32; 12.17) 93555.50 < 0.001 
Education (in years) 14.60 (14; 4.85) 14.88 (14; 5.00) 104861.50 0.49 
 n      % n       % χ2 (df = 1)  
Female gender 213   58.0 342    58.2 0.001 0.97 
Caucasian 299   81.5 493    83.8 0.90 0.34 
Married/de facto 
relationship 
148   40.3 228    38.8 0.23 0.63 
Parenthood (having 
children) 
154   42.0 236    40.1 0.31 0.58 
Unemployed 63    17.7 90     15.6 0.74 0.39 




Table 2. Relevant clinical variables in benzodiazepine users and non-users. 
Variables BDZ users 
(n = 367) 
Mean (Median; SD) 
BDZ non-users 
(n = 588) 





Y-BOCS total score 25.89 (26; 8.03) 25.41 (26; 7.09) 102536.50 0.20 
DY-BOCS aggressive 
obsessions score 
5.68 (6; 5.04) 5.21 (5; 4.97) 101637.00 0.12 
DY-BOCS sexual/moral/ 
religious obsessions score 
4.85 (3; 5.02) 4.02 (0; 4.84) 96733.00 0.004 
DY-BOCS symmetry and 
related obsessions and 
compulsions score 
7.26 (8; 6.81) 7.74 (9; 5.88) 100860.00 0.09 
DY-BOCS contamination 
and cleaning score 
6.13 (6; 5.17) 6.30 (7; 5.19) 106296.00 0.69 
DY-BOCS hoarding score 3.14 (0; 4.27) 3.22 (0; 3.98) 105178.00 0.48 
DY-BOCS miscellaneous 
obsessions and compulsions 
score 
7.36 (8; 4.76) 7.68 (9; 4.68) 103356.00 0.27 
Duration of OCD (in years) 24.65 (23; 13.14) 22.12 (20; 12.60) 95424.00 0.003 
BDI-II score 18.90 (18; 11.87) 15.35 (14; 10.49) 89737.50 < 0.001 
BAI score 18.28 (17; 12.32) 15.06 (13; 10.51) 92363.50 < 0.001 
Number of additional 
medications for OCD 
3.84 (3; 3.01) 1.29 (1; 1.50) 42729.50 < 0.001  
BDZ = Benzodiazepine; Y-BOCS = Yale-Brown Obsessive-Compulsive Scale; DY-BOCS = 
Dimensional Yale-Brown Obsessive-Compulsive Scale; OCD = Obsessive-compulsive disorder; BDI-




Table 3. Lifetime rates of co-occurring anxiety disorders in benzodiazepine users and non-
users.  
 
Co-occurring anxiety disorders BDZ users 
(n = 367) 
BDZ non-users 
(n = 588) 
χ2 
(df = 1) 
p 
N % n %   
Panic disorder with agoraphobia 42 11.4 25 4.3 17.92 < 0.001 
Panic disorder without agoraphobia 15 4.1 29 4.9 0.37 0.55 
Agoraphobia without history of panic disorder 15 4.1 30 5.1 0.52 0.47 
Social anxiety disorder 114 31.1 198 33.7 0.70 0.40 
Specific phobia 107 29.2 189 32.1 0.94 0.33 
Generalized anxiety disorder 126 34.3 195 33.2 0.14 0.71 
Posttraumatic stress disorder 39 10.6 58 9.9 0.14 0.70 





Table 4. Results of the logistic regression analyses predicting use of benzodiazepines.  
 Unstandardised Wald test 
(z-ratio) 
Exp(B) p 











Y-BOCS total score 
Duration of OCD 













BDI-II score 0.01 (0.01) 0.88 1.01 0.38 
BAI score 0.02 (0.01) 2.49 1.02 0.01 
DY-BOCS aggressive obsessions score -0.01 (0.02) -0.50 0.99 0.49 
DY-BOCS sexual/moral/religious obsessions 
score 
0.01 (0.008) 1.87 1.02 0.06 
R2 = 0.44. 
Y-BOCS = Yale-Brown Obsessive-Compulsive Scale; OCD = Obsessive-compulsive disorder; BDI-
II = Beck Depression Inventory; BAI = Beck Anxiety Inventory; DY-BOCS = Dimensional Yale-
Brown Obsessive-Compulsive Scale. 
 
 
